ixekizumab (new, PICO 58). In adults with active AS despite treatment with NSAIDs, we conditionally recommend treatment with TNFi over treatment with secukinumab or ixekizumab (new, PICO 59). In adults with active AS despite treatment with NSAIDs, we conditionally recommend treatment with TNFi over treatment with tofacitinib (new, PICO 60). In adults with active AS despite treatment with NSAIDs, we conditionally recommend treatment with secukinumab or ixekizumab over treatment with tofacitinib